Coherus BioSciences, Inc.
NASDAQ:CHRS
Overview | Financials
Company Name | Coherus BioSciences, Inc. |
Symbol | CHRS |
Currency | USD |
Price | 0.82 |
Market Cap | 94,471,380 |
Dividend Yield | 0% |
52-week-range | 0.66 - 3.7 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Dennis M. Lanfear |
Website | https://www.coherus.com |
An error occurred while fetching data.
About Coherus BioSciences, Inc.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD